Related Experiment Video
Updated: Aug 11, 2026
Harvesting Murine Alveolar Macrophages and Evaluating Cellular Activation Induced by Polyanhydride Nanoparticles
Published on: June 8, 2012
Modulation of ICAM-1 expression in human alveolar macrophages in vitro
M Fattal-German1, F L Ladurie, J Cerrina
1Laboratoire d'Immunologie CNRS URA 1159, Université Paris-XI, Hôpital Marie-Lannelongue, Le Plessis-Robinson, France.
Abstract:
Modulation of intercellular adhesion molecule-1 (ICAM-1) expression may be a basic mechanism by which alveolar macrophages (AMs) regulate the inflammatory process in the lung in response to local stimuli. As a model for studying the anti-inflammatory activity of drugs on human AMs, we investigated the effects of fusafungine, an antibiotic for local use by aerosol with anti-inflammatory properties, and that of the glucocorticoid dexamethasone, on ICAM-1 expression induced in vitro by recombinant interferon-gamma (rIFN-gamma). ICAM-1 protein expression was studied on AMs by means of flow cytometry with an anti-CD54 monoclonal antibody; messenger ribonucleic acid (mRNA) levels were determined by reverse transcriptase-polymerase chain reaction (RT-PCR). ICAM-1 was expressed before culture on 21% of bronchoalveolar lavage (BAL) cells, with low intensity. Culture for 24 h with rIFN-gamma resulted in a significant increase in ICAM-1 protein expression (82% of cells were strongly positive). Fusafungine significantly inhibited rIFN-gamma-induced ICAM-1-protein expression on AMs in a concentration-dependent fashion. The mechanism of ICAM-1 downregulation was mainly post-transcriptional, but also partly transcriptional. By contrast, dexamethasone did not influence rIFN-gamma-induced ICAM-1 expression. This in vitro model using human AMs should prove useful for investigating the cellular and molecular targets of anti-inflammatory drugs.
Insights
Fusafungine, an anti-inflammatory aerosol antibiotic, effectively reduces intercellular adhesion molecule-1 (ICAM-1) expression on human alveolar macrophages (AMs). This action, observed in vitro, suggests a novel mechanism for modulating lung inflammation.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Intercellular adhesion molecule-1 (ICAM-1) expression on alveolar macrophages (AMs) is a key regulator of lung inflammatory responses.
- Understanding drug effects on ICAM-1 is crucial for developing targeted anti-inflammatory therapies.
Purpose of the Study:
- To investigate the in vitro effects of fusafungine and dexamethasone on ICAM-1 expression in human AMs.
- To evaluate fusafungine's anti-inflammatory potential by examining its impact on ICAM-1 induction.
Main Methods:
- Human AMs were cultured and stimulated with recombinant interferon-gamma (rIFN-gamma) to induce ICAM-1 expression.
- ICAM-1 protein levels were quantified using flow cytometry.
- Messenger RNA (mRNA) levels were assessed via reverse transcriptase-polymerase chain reaction (RT-PCR).
Main Results:
- rIFN-gamma significantly increased ICAM-1 protein expression on AMs.
- Fusafungine demonstrated a concentration-dependent inhibition of rIFN-gamma-induced ICAM-1 protein expression.
- Fusafungine's inhibitory mechanism involved both post-transcriptional and transcriptional downregulation of ICAM-1.
- Dexamethasone did not affect rIFN-gamma-induced ICAM-1 expression.
Conclusions:
- Fusafungine exhibits significant anti-inflammatory activity by downregulating ICAM-1 expression in human AMs.
- The study highlights a novel post-transcriptional mechanism of action for fusafungine.
- This in vitro model provides a valuable platform for assessing anti-inflammatory drug efficacy on human AMs.
